Analysts Offer Predictions for GlaxoSmithKline PLC’s FY2017 Earnings (GSK)
GlaxoSmithKline PLC (NYSE:GSK) – Analysts at Leerink Swann lowered their FY2017 earnings per share estimates for GlaxoSmithKline PLC in a research report issued to clients and investors on Monday. Leerink Swann analyst S. Fernandez now expects that the pharmaceutical company will earn $2.84 per share for the year, down from their prior estimate of $2.85.
GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion.
WARNING: “Analysts Offer Predictions for GlaxoSmithKline PLC’s FY2017 Earnings (GSK)” was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/analysts-offer-predictions-for-glaxosmithkline-plcs-fy2017-earnings-gsk.html.
Several other equities analysts also recently issued reports on the company. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Wednesday, October 18th. Morgan Stanley downgraded GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. Argus reaffirmed a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Finally, BidaskClub raised GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the stock. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and an average target price of $44.33.
Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 40.62 on Tuesday. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.53. The company has a market cap of $99.28 billion, a price-to-earnings ratio of 39.36 and a beta of 1.03. The company has a 50 day moving average price of $40.52 and a 200 day moving average price of $41.52.
A number of institutional investors have recently modified their holdings of GSK. Renaissance Technologies LLC lifted its stake in GlaxoSmithKline PLC by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after buying an additional 4,935,900 shares in the last quarter. FMR LLC lifted its stake in GlaxoSmithKline PLC by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after buying an additional 1,389,238 shares in the last quarter. Thrivent Financial For Lutherans lifted its stake in GlaxoSmithKline PLC by 87,023.5% in the 1st quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock valued at $57,884,000 after buying an additional 1,371,490 shares in the last quarter. Bank of America Corp DE lifted its stake in GlaxoSmithKline PLC by 15.8% in the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after buying an additional 934,928 shares in the last quarter. Finally, Federated Investors Inc. PA lifted its stake in GlaxoSmithKline PLC by 22.7% in the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after buying an additional 833,501 shares in the last quarter. 9.31% of the stock is currently owned by hedge funds and other institutional investors.
The business also recently declared a quarterly dividend, which was paid on Thursday, October 12th. Investors of record on Friday, August 11th were paid a $0.491 dividend. The ex-dividend date of this dividend was Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 4.84%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 198.00%.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.